Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy. | Zendy

Stefano Molica | Zendy; Paolo Sportoletti | Zendy; Nicola Di Renzo | Zendy; Pellegrino Musto | Zendy; Fabrizio Pane | Zendy; Francesco Di Raimondo | Zendy

Open Access

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

Author(s) -

Stefano Molica,

Paolo Sportoletti,

Nicola Di Renzo,

Pellegrino Musto,

Fabrizio Pane,

Francesco Di Raimondo

Publication year - 2021

Publication title -

mediterranean journal of hematology and infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 31

ISSN - 2035-3006

DOI - 10.4084/mjhid.2021.042

Subject(s) - medicine , rituximab , venetoclax , pandemic , covid-19 , chronic lymphocytic leukemia , refractory (planetary science) , leukemia , intensive care medicine , immunology , virology , lymphoma , disease , astrobiology , outbreak , infectious disease (medical specialty) , physics

With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies (1-2). Given the multiple immune defects characterizing chronic lymphocytic leukaemia (CLL), it is considered that patients with this form of leukemia have a high-risk of suffering severe forms of COVID-19 (3-4).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research